New Prognostic and Predictive Markers in Cancer Progression
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions suc...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (294 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546334004498 |
---|---|
ctrlnum |
(CKB)5400000000045439 (oapen)https://directory.doabooks.org/handle/20.500.12854/68373 (EXLCZ)995400000000045439 |
collection |
bib_alma |
record_format |
marc |
spelling |
Costantini, Susan edt New Prognostic and Predictive Markers in Cancer Progression Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (294 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types. English Medicine bicssc MSI2 OSCC oral cancer musashi 2 prognosis N-cadherin EMT breast cancer new metastasis eribulin blood biomarker bladder cancer immune checkpoint inhibitor CD8+ T effector cells microRNA biomarkers head and neck cancer laryngeal cancer prediction metastasis lifestyle habit chemo-/radio resistance therapeutic target AKT AR castration-resistant prostate cancer (CRPC) MAPK mTOR PI3K prostate cancer therapeutic resistance WNT miRNA melanoma melanoma resistance to MAPK/MEK inhibitors resistance to immune checkpoint inhibitors TNBC BRCA1/2 HRR PDL1 TILs PI3KCA PTEN CTCs CSC pancreatic cancer K-RAS oncogene oncogene dependency targeted therapies genomic mutations transcriptomics metabolomics selenoproteins cancer HUB nodes major histocompatibility complex (MHC) human leukocyte antigen (HLA) antigen processing machinery (APM) molecules carcinogenesis tumor predisposition cancer immunotherapy pheochromocytoma paraganglioma head and neck neoplasms head and neck tumors genetic syndromes mutations hyperglycemia cardioncology nivolumab cytokines cardiotoxicity acetyltransferase cancer prognosis NAA10 3-03943-977-4 3-03943-978-2 Budillon, Alfredo edt Costantini, Susan oth Budillon, Alfredo oth |
language |
English |
format |
eBook |
author2 |
Budillon, Alfredo Costantini, Susan Budillon, Alfredo |
author_facet |
Budillon, Alfredo Costantini, Susan Budillon, Alfredo |
author2_variant |
s c sc a b ab |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
New Prognostic and Predictive Markers in Cancer Progression |
spellingShingle |
New Prognostic and Predictive Markers in Cancer Progression |
title_full |
New Prognostic and Predictive Markers in Cancer Progression |
title_fullStr |
New Prognostic and Predictive Markers in Cancer Progression |
title_full_unstemmed |
New Prognostic and Predictive Markers in Cancer Progression |
title_auth |
New Prognostic and Predictive Markers in Cancer Progression |
title_new |
New Prognostic and Predictive Markers in Cancer Progression |
title_sort |
new prognostic and predictive markers in cancer progression |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (294 p.) |
isbn |
3-03943-977-4 3-03943-978-2 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT costantinisusan newprognosticandpredictivemarkersincancerprogression AT budillonalfredo newprognosticandpredictivemarkersincancerprogression |
status_str |
n |
ids_txt_mv |
(CKB)5400000000045439 (oapen)https://directory.doabooks.org/handle/20.500.12854/68373 (EXLCZ)995400000000045439 |
carrierType_str_mv |
cr |
is_hierarchy_title |
New Prognostic and Predictive Markers in Cancer Progression |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796651979343134720 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04583nam-a2201225z--4500</leader><controlfield tag="001">993546334004498</controlfield><controlfield tag="005">20231214133144.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045439</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/68373</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045439</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Costantini, Susan</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Prognostic and Predictive Markers in Cancer Progression</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (294 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MSI2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OSCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">musashi 2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">N-cadherin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EMT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">new metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">eribulin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD8+ T effector cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">laryngeal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prediction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lifestyle habit</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemo-/radio resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic target</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AKT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">castration-resistant prostate cancer (CRPC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MAPK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">WNT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma resistance to MAPK/MEK inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance to immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TNBC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BRCA1/2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HRR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PDL1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TILs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3KCA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PTEN</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CTCs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CSC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pancreatic cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">K-RAS oncogene</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncogene dependency</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">selenoproteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HUB nodes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">major histocompatibility complex (MHC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human leukocyte antigen (HLA)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen processing machinery (APM) molecules</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carcinogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor predisposition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pheochromocytoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">paraganglioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">head and neck tumors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic syndromes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hyperglycemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardioncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nivolumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytokines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acetyltransferase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NAA10</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-977-4</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-978-2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Budillon, Alfredo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Costantini, Susan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Budillon, Alfredo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:44:29 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338232780004498&Force_direct=true</subfield><subfield code="Z">5338232780004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338232780004498</subfield></datafield></record></collection> |